ERBB2 and breast cancer: In April 2019, the patient was eligible for the SOPHIA clinical trial, a randomized, open-label, phase III trial evaluating margetuximab+chemotherapy vs. trastuzumab+chemotherapy of physician choice in patients with pretreated HER2+ metastatic BC; prior brain metastases were allowed if treated or stable.